Chordate Medical has appointed Narro Trading Est. (Narro Medical) as a non-exclusive distributor in Saudi Arabia. Narro Medical will initially focus on the migraine segment, and the qualification process as a distributor has been underway for some time.
“We already have a distributor in Saudi Arabia, but we see a need to increase focus and expertise in the neurology field. Narro Medical fits well into that strategy and is currently in the final stages of the qualification process. This includes demonstrating effective sales activities in the field, taking over the work with prospective customers we have previously engaged, and placing qualifying orders for demo equipment and stock – something they have successfully accomplished so far,” says Anders Weilandt, CEO of Chordate Medical.
Ozilia is currently offered as a rhinitis treatment at nine clinics in Jeddah and Riyadh. In September 2024, Chordate received its first order for Ozilia migraine treatment in Saudi Arabia, and shortly thereafter, the Saudi Food and Drug Authority (SFDA) approved the company’s application for market authorization for the migraine indication.